Rocket Pharmaceuticals
RCKT
177 hedge funds and large institutions have $3.41B invested in Rocket Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 60 funds opening new positions, 52 increasing their positions, 49 reducing their positions, and 9 closing their positions.
567% more first-time investments, than exits
New positions opened: 60 | Existing positions closed: 9
161% more capital inflows, than outflows
Capital inflows: $450M | Capital outflows: $172M
133% more funds holding in top 10
Funds holding in top 10: 3 → 7 (+4)
40% more funds holding
Funds holding: 126 → 177 (+51)
3.72% more ownership
Funds ownership: 100.12% → 103.84% (+3.7%)
6% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 49
36% less call options, than puts
Call options by funds: $7.09M | Put options by funds: $11.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA Capital Management
Boston,
Massachusetts
|
+$77.9M |
| 2 |
Perceptive Advisors
New York
|
+$44M |
| 3 |
Janus Henderson Group
London,
|
+$43.7M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$40.8M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$36.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Eventide Asset Management
Boston,
Massachusetts
|
-$35.4M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
-$20.1M |
| 3 |
State Street
Boston,
Massachusetts
|
-$17.4M |
| 4 |
FM
Frazier Management
Seattle,
Washington
|
-$13.1M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$11M |
RCKT Hedge Fund Activity: Q4 2020 in Review
177 of the 5,678 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q4 2020, worth a combined $3.41B — up 170% from $1.26B a quarter earlier.
Buyers outnumbered sellers: 60 funds opened new RCKT positions and 9 closed out — a net gain of 51 holders — while 52 added to existing stakes and 49 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $77.9M. The largest seller was Eventide Asset Management, exiting entirely with an estimated $35.4M sold.
- 177 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q4 2020, up from 126 in Q3 2020.
- Funds reported $3.41B of Rocket Pharmaceuticals stock for Q4 2020, up 170% quarter-over-quarter.
- 60 funds opened new Rocket Pharmaceuticals positions in Q4 2020 and 9 closed out, a net change of +51 holders.
- The largest Rocket Pharmaceuticals buyer in Q4 2020 was RA Capital Management, an estimated $77.9M added.
- The largest Rocket Pharmaceuticals seller in Q4 2020 was Eventide Asset Management, an estimated $35.4M sold.
Based on aggregated 13F filings for Q4 2020.